Market Access News | pharmaphorum

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Torso of doctor with surgical gloves holding prescription pill bottle in one hand and multiple $100 bills in the other

Latest Medicare pricing cuts promise $12bn in savings

The CMS has revealed the prices for the second batch of 15 drugs going through Medicare's negotiation process, promising net savings of 44% on 2024.

News

NICE backs NHS use of Autolus' leukaemia CAR-T

Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.

News

Innovent files high-dose mazdutide for obesity in China

Innovent has filed a new high-strength version of its weight-loss drug mazdutide in China, aiming to help people with severe obesity.

News

Boy in wheelchair, only lower half of his body visible

Novartis' SMA gene therapy cleared for wider use in US

A new FDA approval means Novartis now has a gene therapy option for almost everyone with spinal muscular atrophy (SMA), regardless of their age.

News

Overweight man leans on office desk with female co-worker

Waltz dances into direct-to-employer sales of obesity drugs

Waltz Health is planning to disrupt the weight-loss therapy market in the US with a new direct-to-employer sales channel.

Otsuka joins IgAN market with Voyxact approval in US

Latest Medicare pricing cuts promise $12bn in savings

NICE backs NHS use of Autolus' leukaemia CAR-T

Innovent files high-dose mazdutide for obesity in China

Novartis' SMA gene therapy cleared for wider use in US

Waltz dances into direct-to-employer sales of obesity drugs

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks